Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Finished Goods: 2023-2024

Historic Finished Goods for Krystal Biotech (KRYS) over the last 2 years, with Dec 2024 value amounting to $2.1 million.

  • Krystal Biotech's Finished Goods rose 126.57% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 126.57%. This contributed to the annual value of $2.1 million for FY2024, which is 239.07% up from last year.
  • According to the latest figures from FY2024, Krystal Biotech's Finished Goods is $2.1 million, which was up 239.07% from $627,000 recorded in FY2023.
  • In the past 5 years, Krystal Biotech's Finished Goods registered a high of $2.1 million during FY2024, and its lowest value of $627,000 during FY2023.
  • Moreover, its 2-year median value for Finished Goods was $1.4 million (2023), whereas its average is $1.4 million.
  • Data for Krystal Biotech's Finished Goods shows a peak YoY soared of 239.07% (in 2024) over the last 5 years.
  • Krystal Biotech's Finished Goods (Yearly) stood at $627,000 in 2023, then skyrocketed by 239.07% to $2.1 million in 2024.